CN111297853A - 沙坦类物质在制备预防和/或治疗新型冠状病毒肺炎的药物中的应用 - Google Patents

沙坦类物质在制备预防和/或治疗新型冠状病毒肺炎的药物中的应用 Download PDF

Info

Publication number
CN111297853A
CN111297853A CN202010223147.2A CN202010223147A CN111297853A CN 111297853 A CN111297853 A CN 111297853A CN 202010223147 A CN202010223147 A CN 202010223147A CN 111297853 A CN111297853 A CN 111297853A
Authority
CN
China
Prior art keywords
sartan
medicine
novel coronavirus
substances
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010223147.2A
Other languages
English (en)
Inventor
张伟
舒炎
韩林志
周淦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xiangya Hospital of Central South University
Original Assignee
Xiangya Hospital of Central South University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xiangya Hospital of Central South University filed Critical Xiangya Hospital of Central South University
Priority to CN202010223147.2A priority Critical patent/CN111297853A/zh
Publication of CN111297853A publication Critical patent/CN111297853A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及沙坦类物质在制备预防和/或治疗新型冠状病毒肺炎的药物中的应用，属于药物制备技术领域。本发明提供了一种沙坦类物质的新用途，能够提供一种用于治疗新型冠状病毒肺炎的药物，所述药物对于治疗新型冠状病毒肺炎有明显临床疗效。

Description

沙坦类物质在制备预防和/或治疗新型冠状病毒肺炎的药物 中的应用
技术领域
本发明涉及药物制备技术领域，具体涉及沙坦类物质在制备预防和/或治疗新型冠状病毒肺炎的药物中的应用。
背景技术
2019新型冠状病毒(2019-nCoV)是2019年在人体中发现的冠状病毒新毒株，主要通过呼吸道飞沫传播和接触传播。目前对于新型冠状病毒所致疾病没有特异治疗方法，也没有用于治疗新型冠状病毒肺炎的药物。
发明内容
本发明的目的在于提供沙坦类物质在制备预防和/或治疗新型冠状病毒肺炎的药物中的应用。本发明提供了一种沙坦类物质的新用途，能够提供一种用于治疗新型冠状病毒肺炎的药物，所述药物对于治疗新型冠状病毒肺炎有明显临床疗效。
本发明提供了沙坦类物质在制备预防和/或治疗新型冠状病毒肺炎的药物中的应用。
优选的是，所述沙坦类物质包括厄贝沙坦和/或洛沙坦。
优选的是，所述药物还包括赋形剂。
优选的是，所述赋形剂包括淀粉。
优选的是，所述药物的剂型包括胶囊和颗粒。
本发明提供了沙坦类物质在制备预防和/或治疗新型冠状病毒肺炎的药物中的应用。本发明提供了一种沙坦类物质的新用途，能够提供一种用于治疗新型冠状病毒肺炎的药物，所述药物对于治疗新型冠状病毒肺炎有明显临床疗效。试验结果表明，本发明应用制备得到的药物后，治疗组肺损伤能够有效改善，重症肺炎发生率较对照组明显降低。
附图说明
图1为本发明提供的厄贝沙坦化学结构图；
图2为本发明提供的洛沙坦钾化学结构图。
具体实施方式
本发明提供了沙坦类物质在制备预防和/或治疗新型冠状病毒肺炎的药物中的应用。
在本发明中，所述沙坦类物质包括厄贝沙坦和/或洛沙坦。本发明对所述厄贝沙坦和洛沙坦的来源没有特殊限定，采用本领域技术人员熟知的常规厄贝沙坦和洛沙坦市售产品即可。本发明厄贝沙坦，分子式是C25H28N6O。化学名称为2-丁基-3-4-2-(1H-四唑-5-基)苯基苄基-1,3-二氮杂螺-4.4壬-1-烯-4-酮。化学结构如图1所示。本发明所述洛沙坦优选还包括洛沙坦钾，分子式为C22H22ClKN6O，化学名称为2-丁基-4-氯-1-[[2'-(1H-四唑-5-基)[1，1′-联苯基]-4-基]甲基]-1H-咪唑-5-甲醇单钾盐，化学结构如图2所示。
在本发明中，所述药物优选还包括赋形剂。在本发明中，所述赋形剂优选包括淀粉。在本发明中，所述药物的剂型包括胶囊和颗粒。本发明对所述药物的制备方法没有特殊限定，采用本领域技术人员熟知的常规胶囊或颗粒的制备方法即可。本发明所述胶囊优选为淀粉胶囊。
下面结合具体实施例对本发明所述的沙坦类物质在制备预防和/或治疗新型冠状病毒肺炎的药物中的应用做进一步详细的介绍，本发明的技术方案包括但不限于以下实施例。
实施例1
沙坦类药物是广泛用于治疗高血压的较安全和有效的药物。目前并没有将沙坦类药物用于2019-nCoV新冠肺炎治疗药物的制备中的应用。
本发明对2019-nCoV新冠肺炎受试组患者在标准治疗方案中加入本发明药物，对比受试组与普通治疗组之间的区别，发现治疗组肺损伤能够有效改善，重症肺炎发生率较对照组明显降低。
通过观察了1001例肺炎患者，其中122例患者服用沙坦类药物。对比发现用药与否明显影响病情的严重程度，使用沙坦类药物的患者肺炎严重程度比未用沙坦类患者明显降低。
以上所述仅是本发明的优选实施方式，应当指出，对于本技术领域的普通技术人员来说，在不脱离本发明原理的前提下，还可以做出若干改进和润饰，这些改进和润饰也应视为本发明的保护范围。

Claims (5)

1.沙坦类物质在制备预防和/或治疗新型冠状病毒肺炎的药物中的应用。
2.根据权利要求1所述的应用，其特征在于，所述沙坦类物质包括厄贝沙坦和/或洛沙坦。
3.根据权利要求1所述的应用，其特征在于，所述药物还包括赋形剂。
4.根据权利要求3所述的应用，其特征在于，所述赋形剂包括淀粉。
5.根据权利要求1所述的应用，其特征在于，所述药物的剂型包括胶囊和颗粒。
CN202010223147.2A 2020-03-26 2020-03-26 沙坦类物质在制备预防和/或治疗新型冠状病毒肺炎的药物中的应用 Pending CN111297853A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010223147.2A CN111297853A (zh) 2020-03-26 2020-03-26 沙坦类物质在制备预防和/或治疗新型冠状病毒肺炎的药物中的应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010223147.2A CN111297853A (zh) 2020-03-26 2020-03-26 沙坦类物质在制备预防和/或治疗新型冠状病毒肺炎的药物中的应用

Publications (1)

Publication Number Publication Date
CN111297853A true CN111297853A (zh) 2020-06-19

Family

ID=71151531

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010223147.2A Pending CN111297853A (zh) 2020-03-26 2020-03-26 沙坦类物质在制备预防和/或治疗新型冠状病毒肺炎的药物中的应用

Country Status (1)

Country Link
CN (1) CN111297853A (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113150130A (zh) * 2021-01-31 2021-07-23 中南大学湘雅医院 新型冠状病毒单克隆抗体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101002766A (zh) * 2000-08-22 2007-07-25 贝林格尔英格海姆法玛两合公司 血管紧张素ⅱ拮抗剂与血管紧张素ⅰ转换酶抑制剂的药物结合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101002766A (zh) * 2000-08-22 2007-07-25 贝林格尔英格海姆法玛两合公司 血管紧张素ⅱ拮抗剂与血管紧张素ⅰ转换酶抑制剂的药物结合物

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
A H JAN DANSER 等: "Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers", 《HYPERTENSION》 *
DAVID GURWITZ: "Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics", 《 DRUG DEVELOPMENT RESEARCH》 *
施仲伟: "合并高血压的新型冠状病毒肺炎患者无需停用血管紧张素转换酶抑制剂和血管紧张素受体拮抗剂类药物", 《中华高血压杂志》 *
易湛苗 等: "新型冠状病毒肺炎疫情应对的循证药学实践", 《中国药房》 *
杨宝学 等: "《实用临床药物学》", 31 July 2018, 中国医药科技出版社 *
陈硕等: "血管紧张素转换酶2和新型冠状病毒肺炎的关系及降压药物对血管紧张素转换酶2的影响", 《中华高血压杂志》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113150130A (zh) * 2021-01-31 2021-07-23 中南大学湘雅医院 新型冠状病毒单克隆抗体及其应用

Similar Documents

Publication Publication Date Title
JP5699135B2 (ja) 高病原性感染症を予防および治療するための薬剤
WO2021155777A1 (zh) 药物组合物在预防和治疗新型冠状病毒肺炎中的应用
KR20170009276A (ko) 호흡기 바이러스성 질환 치료를 위한 라도티닙의 용도
CN110520133A (zh) 包含钠-葡萄糖协同转运蛋白-2抑制剂及血管紧张素受体阻滞剂的医药组合物
WO2022039619A1 (ru) Противовирусное средство для комбинированной терапии covid-19 (sars-cov-2)
EP4144353A1 (en) Coronavirus infection therapeutic agent formed through combination of pyrazine derivative and another coronavirus infection therapeutic drug
CN111297853A (zh) 沙坦类物质在制备预防和/或治疗新型冠状病毒肺炎的药物中的应用
CN114796177A (zh) 抗冠状病毒药物和应用
JP2022019937A (ja) ヒト又は動物の慢性若しくは急性のウイルス感染症及び／又は敗血症の予防若しくは治療のための組成物
CN104080451A (zh) 吲哚异羟肟酸和吲哚啉异羟肟酸于治疗心脏衰竭或神经损伤的用途
RU2745986C1 (ru) Противокоронавирусное средство для комбинированной терапии COVID-19 (SARS-CoV-2) и способ лечения
WO2023023651A1 (en) Quinacrine and derivatives thereof for treatment of viral infections
US10045984B2 (en) Combination therapy
Azka et al. Antiviral Therapy in Corona Virus Disease-19 (Covid-19)
Scott et al. Tongue swelling complicating management of a ventilated patient with acute respiratory distress syndrome secondary to novel influenza A (H1N1)
CN105362284B (zh) 阿奇霉素和泰利霉素在抗埃博拉病毒感染中的应用
CN102716128A (zh) 一种治疗哮喘的药用组合物
WO2021258206A1 (en) Water-soluble artesunate-based therapy for coronavirus infection
EP1875918B1 (en) New use of ammonium chloride for the therapy of total or partial hepatic failure and necrosis
RU2746161C1 (ru) Фармацевтический набор для комбинированной терапии COVID-19 (SARS-CoV-2) и способ его применения
RU2742116C1 (ru) Противокоронавирусное средство для комбинированной терапии COVID-19 (SARS-CoV-2).
EA042258B1 (ru) ПРОТИВОКОРОНАВИРУСНОЕ СРЕДСТВО ДЛЯ КОМБИНИРОВАННОЙ ТЕРАПИИ COVID-19 (SARS-CoV-2) И СПОСОБ ЛЕЧЕНИЯ
Kavitha Drug corner remdesivir
CN103933034B (zh) 一种含有木犀草素的药物组合物及应用
MISUSE First flu treatment approved in 20 years

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20200619